Allakos Inc. (ALLK) |
|
4.61 -0.12 (-2.54%)
|
03-24 16:00 |
|
Open: |
4.68 |
Pre. Close: |
4.73 |
|
High:
|
4.78 |
Low:
|
4.505 |
|
Volume:
|
757,314 |
Market Cap:
|
395(M) |
|
|
|
Technical analysis |
as of: 2023-03-24 4:23:55 PM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 6.87  One year: 7.87 |
| Support: |
Support1: 4.5 Support2: 3.74 |
| Resistance: |
Resistance1: 5.88 Resistance2: 6.73 |
| Pivot: |
5.37 |
| Moving Average: |
MA(5): 4.8 MA(20): 5.5
MA(100): 6.87 MA(250): 5.3 |
| MACD: |
MACD(12,26): -0.5 Signal(9): -0.4 |
| Stochastic oscillator: |
%K(14,3): 4 %D(3): 4.5 |
| RSI: |
RSI(14): 29.5 |
| 52-week: |
High: 8.72 Low: 2.53 |
| Average Vol(K): |
3-Month: 968 (K) 10-Days: 986 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ALLK ] has closed above bottom band by 12.2%. Bollinger Bands are 31.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
4.79 - 4.81 |
4.81 - 4.83 |
|
Low:
|
4.44 - 4.47 |
4.47 - 4.5 |
|
Close:
|
4.57 - 4.61 |
4.61 - 4.65 |
|
Company Description |
|
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; a Phase II/III study for eosinophilic esophagitis; and a Phase II clinical study to atopic dermatitis and chronic spontaneous urticaria. It is also developing lirentelimab (AK002) for the treatment of mast cell gastrointestinal disease, chronic urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis; and AK006 to treat allergic and inflammatory diseases. The company was incorporated in 2012 and is headquartered in Redwood City, California. |
Headline News |
Tue, 07 Mar 2023
Why Allakos Stock Was Heating Up Today - The Motley Fool
Tue, 07 Mar 2023
Piper Sandler Initiates Coverage of Allakos (ALLK) with Overweight ... - Nasdaq
Tue, 07 Mar 2023
Allakos Inc. (NASDAQ:ALLK) Short Interest Update - MarketBeat
Mon, 06 Mar 2023
Logos Global Management LP acquires a stake in Allakos Inc ... - Best Stocks
Mon, 06 Mar 2023
Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results - Yahoo Finance
Sun, 05 Mar 2023
Logos Global Management LP Takes Position in Allakos Inc ... - MarketBeat
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
86 (M) |
| Shares Float |
42 (M) |
|
% Held by Insiders
|
4.3 (%) |
|
% Held by Institutions
|
91.3 (%) |
|
Shares Short
|
3,570 (K) |
|
Shares Short P.Month
|
2,700 (K) |
Stock Financials |
|
EPS
|
-5.97 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
3.64 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-43.8 |
|
Return on Equity (ttm)
|
-84.7 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-3.69 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-280 (M) |
|
Levered Free Cash Flow
|
-172 (M) |
Stock Valuations |
|
PE Ratio
|
-0.78 |
|
PEG Ratio
|
-0.1 |
|
Price to Book value
|
1.26 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-1.42 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
